Consistently, the European Society for Medical Oncology (ESMO) recognizes HER2-low as a heterogenous group of tumors influenced by HR status and states that current data do not support its classification as a separate breast cancer subtype [11,19]. This evidence concerns the gene ERBB2 and breast carcinoma.